Form 4: UNITED THERAPEUTICS CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 20, 2026.

Summary

  • Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on July 20, 2026; holds 333,943 after (Indirect).
  • Open-market sale: disposed of 1,831 Common Stock at $529.19 ($968,945) on July 20, 2026; holds 332,112 after (Indirect).
  • Open-market sale: disposed of 960 Common Stock at $529.85 ($508,657) on July 20, 2026; holds 331,152 after (Indirect).
  • Open-market sale: disposed of 1,660 Common Stock at $531.08 ($881,588) on July 20, 2026; holds 329,492 after (Indirect).
  • Open-market sale: disposed of 1,874 Common Stock at $532.07 ($997,105) on July 20, 2026; holds 327,618 after (Indirect).
  • Open-market sale: disposed of 1,686 Common Stock at $533.03 ($898,683) on July 20, 2026; holds 325,932 after (Indirect).
  • Open-market sale: disposed of 889 Common Stock at $534.13 ($474,838) on July 20, 2026; holds 325,043 after (Indirect).
  • Open-market sale: disposed of 520 Common Stock at $535.20 ($278,306) on July 20, 2026; holds 324,523 after (Indirect).
  • Open-market sale: disposed of 80 Common Stock at $536.41 ($42,913) on July 20, 2026; holds 324,443 after (Indirect).
  • Option exercise/conversion: disposed of 9,500 Stock Option on July 20, 2026; holds 312,910 after (Indirect).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,051,035 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Martine A Rothblatt — Director, Officer (Chairperson & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-20Option exercise/conversionCommon Stock9,500$135$1.3M333,943
2026-07-20Open-market saleCommon Stock1,831$529$968.9K332,112
2026-07-20Open-market saleCommon Stock960$530$508.7K331,152
2026-07-20Open-market saleCommon Stock1,660$531$881.6K329,492
2026-07-20Open-market saleCommon Stock1,874$532$997.1K327,618
2026-07-20Open-market saleCommon Stock1,686$533$898.7K325,932
2026-07-20Open-market saleCommon Stock889$534$474.8K325,043
2026-07-20Open-market saleCommon Stock520$535$278.3K324,523
2026-07-20Open-market saleCommon Stock80$536$42.9K324,443
2026-07-20Option exercise/conversionStock Option9,500——312,910

Key Dates

DateDescription
2026-07-20Option exercise/conversion (9,500 shares)
2026-07-20Open-market sale (1,831 shares)
2026-07-20Open-market sale (960 shares)
2026-07-20Open-market sale (1,660 shares)
2026-07-20Open-market sale (1,874 shares)
2026-07-20Open-market sale (1,686 shares)
2026-07-20Open-market sale (889 shares)
2026-07-20Open-market sale (520 shares)
2026-07-20Open-market sale (80 shares)
2026-07-20Option exercise/conversion (9,500 shares)

Keywords

insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.